271 related articles for article (PubMed ID: 28982361)
1. Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized tumor tissue.
Sims LB; Huss MK; Frieboes HB; Steinbach-Rankins JM
J Nanobiotechnology; 2017 Oct; 15(1):67. PubMed ID: 28982361
[TBL] [Abstract][Full Text] [Related]
2. Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer.
Sims LB; Curtis LT; Frieboes HB; Steinbach-Rankins JM
J Nanobiotechnology; 2016 Apr; 14():33. PubMed ID: 27102372
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type.
Sims LB; Curry KC; Parupalli S; Horner G; Frieboes HB; Steinbach-Rankins JM
Pharm Res; 2019 Mar; 36(5):66. PubMed ID: 30868271
[TBL] [Abstract][Full Text] [Related]
4. Non-specific binding and steric hindrance thresholds for penetration of particulate drug carriers within tumor tissue.
Dancy JG; Wadajkar AS; Schneider CS; Mauban JRH; Goloubeva OG; Woodworth GF; Winkles JA; Kim AJ
J Control Release; 2016 Sep; 238():139-148. PubMed ID: 27460683
[TBL] [Abstract][Full Text] [Related]
5. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
Gullotti E; Park J; Yeo Y
Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
[TBL] [Abstract][Full Text] [Related]
6. Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug.
Saadati R; Dadashzadeh S; Abbasian Z; Soleimanjahi H
Pharm Res; 2013 Apr; 30(4):985-95. PubMed ID: 23184228
[TBL] [Abstract][Full Text] [Related]
7. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
8. Modeling of nanoparticle transport through the female reproductive tract for the treatment of infectious diseases.
Sims LB; Miller HA; Halwes ME; Steinbach-Rankins JM; Frieboes HB
Eur J Pharm Biopharm; 2019 May; 138():37-47. PubMed ID: 30195726
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
10. Enhanced uptake in 2D- and 3D- lung cancer cell models of redox responsive PEGylated nanoparticles with sensitivity to reducing extra- and intracellular environments.
Conte C; Mastrotto F; Taresco V; Tchoryk A; Quaglia F; Stolnik S; Alexander C
J Control Release; 2018 May; 277():126-141. PubMed ID: 29534890
[TBL] [Abstract][Full Text] [Related]
11. Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization.
Steinbach JM; Seo YE; Saltzman WM
Acta Biomater; 2016 Jan; 30():49-61. PubMed ID: 26602822
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Lin TsT; Gao DY; Liu YC; Sung YC; Wan D; Liu JY; Chiang T; Wang L; Chen Y
J Control Release; 2016 Jan; 221():62-70. PubMed ID: 26551344
[TBL] [Abstract][Full Text] [Related]
14. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers.
Geldenhuys W; Wehrung D; Groshev A; Hirani A; Sutariya V
Pharm Dev Technol; 2015 Jun; 20(4):497-506. PubMed ID: 24597667
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Antitumor Efficacy and Reduced Toxicity of Docetaxel Loaded Estradiol Functionalized Stealth Polymeric Nanoparticles.
Jain S; Spandana G; Agrawal AK; Kushwah V; Thanki K
Mol Pharm; 2015 Nov; 12(11):3871-84. PubMed ID: 26375023
[TBL] [Abstract][Full Text] [Related]
16. Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.
Li Z; Huang H; Huang L; Du L; Sun Y; Duan Y
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28406431
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
19. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
20. Delivery and short-term maternal and fetal safety of vaginally administered PEG-PLGA nanoparticles.
Irvin-Choy NS; Nelson KM; Gleghorn JP; Day ES
Drug Deliv Transl Res; 2023 Dec; 13(12):3003-3013. PubMed ID: 37365402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
